• About Us
    • Members
    • Constitution
    • Leadership
    • HQ Structure
    • Sponsors
  • Meetings
    • CSEA3 Annual Congress 2026​
    • Expert Meeting 2025
  • Projects
    • CARES registry
    • CASA-IG guidelines
    • SEASON survey
  • Resources
    • Recommended Research Articles
  • About Us
    • Members
    • Constitution
    • Leadership
    • HQ Structure
    • Sponsors
  • Meetings
    • CSEA3 Annual Congress 2026​
    • Expert Meeting 2025
  • Projects
    • CARES registry
    • CASA-IG guidelines
    • SEASON survey
  • Resources
    • Recommended Research Articles
Get in touch
Insights

article

article

Allergen Immunotherapy for Asthma

article

AIT 2023: Current innovation and future outlook

article

House dust mite SCIT reduces asthma risk and significantly improves long-term rhinitis and asthma control-A RWE study

article

Harnessing mass spectrometric methods for exquisite allergen product characterization

article

Improved quality control of allergen products: Assessing the molecular allergen composition by mass spectrometry

article

One-strength dose escalation of house dust mite depot product for subcutaneous immunotherapy is safe and tolerable

article

Six Injections of Modified Adjuvanted PQ Grass Is Effective and Well-Tolerated in a Pivotal Phase III Trial

article

Personalised therapeutic approaches for asthma

article

Update on HDM Allergy: Principal Changes over the Years

Load More

Wrocław, PL

53-201 Wrocław, Al. Gen. Józefa Hallera 95, Poland

Registered in the National Court Register (KRS) under No. 0000304933

contact@csea3.eu

Members
MEETINGS
Projects
Leadership
sponsors
©2025
CSEA3. All rights reserved.
©2025
Payment policy, terms and conditions
top

Inactive

Inactive

Office

The Central & Southern European Allergy and Asthma Alliance (CSEA3)
headquartered at 53-201 Wrocław,
al. Gen. Józefa Hallera 95, Poland.
Registered in the Commercial Register (KRS) under No. 0000304933
contact@csea3.eu

Let's stay in touch!

Contact us